AlphAIAlphAI — Financial news for AI agents
prnewswire.comOCT 142 min read$VKTX

Viking Therapeutics Announces Initiation of VK2735 Oral Phase 3 Clinical Program in Patients with Obesity

Viking Therapeutics (VKTX) has started Phase 3 trials for its oral obesity drug, VK2735. The SUNRISE program includes two studies: one for obese adults without diabetes and another for those with type 2 diabetes. Each trial will enroll 560 adults, testing four dose levels. The primary goal is to measure weight change after 68 weeks. Viking aims to expand treatment options for obesity with this once-daily oral therapy.

Original reporting
prnewswire.com
Published Oct 14, 2026, 11:05 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 14, 2026, 11:07 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Viking Therapeutics Announces Initiation of VK2735 Oral Phase 3 Clinical Program in Patients with Obesity — source image
Source · prnewswire.com
Decision brief

The 30-second read

$VKTXBullishMed
01

Why it matters

The Phase 3 launch is a material corporate milestone that could drive short‑term price appreciation and longer‑term valuation uplift if data are positive.

02

Market read

First‑report of a Phase 3 trial start for a high‑profile obesity drug, offering a fresh catalyst for VKTX and related biotech peers.

03

What to watch

Potential competition from other oral GLP‑1 agents and regulatory timelines.

Relevance 8/10Novelty 8/10Timing: today

Background

Viking Therapeutics (NASDAQ:VKTX) is a clinical‑stage biotech focused on metabolic disorders. The oral dual GLP‑1/GIP agonist VK2735 has shown promising Phase 2 results.

Company-level read

Ticker impact

$VKTXBullishHigh confidence
Context

Viking Therapeutics announced the initiation of the Phase 3 SUNRISE oral VK2735 program for obesity and type‑2 diabetes.

Expected impact

upside pressure as the market prices in trial progress

Evidence & confidence

Phase 3 initiation signals advancement toward commercialization; biotech stocks typically rally on such milestones.

Market effects

Sector

Strengthens the obesity‑treatment pipeline and may boost peer GLP‑1/GIP biotech stocks.

Regional

Positive for US biotech sector; limited immediate effect elsewhere.

Global

Adds to global interest in oral GLP‑1/GIP therapies.

Counterpoint

What could challenge this read

If Phase 3 fails to meet endpoints, the stock could tumble sharply.

Key entities

  • Company
    Viking Therapeutics, Inc.

    Clinical‑stage biotech developing VK2735 for obesity.

  • Drug
    VK2735

    Oral dual GLP‑1/GIP receptor agonist in Phase 3 trials.

Read at source← All news

StoryViking Therapeutics starts Phase 3 SUNRISE program for oral obesity drug VK2735

Also covered by

3 outlets

Related articles

OCT 14
$VKTXMed

Viking Launches Phase 3 SUNRISE Program For Oral Obesity Drug VK2735

Viking Therapeutics (VKTX) began Phase 3 trials for its obesity drug VK2735, testing oral formulations in two 68-week studies with 560 adults each. The trials aim to assess efficacy and safety, with primary endpoints measuring weight change. VK2735 previously showed promising results in a Phase 2 study. The company reported $502M in cash reserves as of June 30, 2026, with its stock trading between $25.77 and $43.15 over the past year.

rttnews.com4 min
OCT 14
$VKTXMedAI 8/10

Viking’s Key Obesity Pill Enters Phase 3 Trial – Here’s What Investors Need To Know

Viking Therapeutics (VKTX) has begun Phase 3 trials for its obesity pill, VK2735, competing with Eli Lilly (LLY) and Novo Nordisk (NVO). The company aims to offer both oral and injectable treatments, but regulatory approval depends on trial success. VKTX shares are down 24% this year, underperforming LLY but outperforming NVO. Retail sentiment on Stocktwits is bearish.

finance.yahoo.com1 min
OCT 14
$VKTXMed

Viking Therapeutics Announces Initiation of VK2735 Oral Phase 3

Viking Therapeutics (VKTX) has started Phase 3 trials for its oral obesity drug VK2735, targeting adults with and without type 2 diabetes. The SUNRISE-1 and SUNRISE-2 studies will evaluate the drug's efficacy and safety over 68 weeks, with primary endpoints measuring body weight change. Viking aims to expand treatment options for obesity with this once-daily oral therapy, complementing its subcutaneous formulation in Phase 3 trials.

gurufocus.com2 min
OCT 14
$VKTXMedAI 8/10

Viking Therapeutics launches phase 3 trials for oral obesity drug

Viking Therapeutics (VKTX) began Phase 3 trials for its oral obesity drug VK2735, targeting metabolic disorders. The SUNRISE program includes two studies with 560 participants each, focusing on weight loss and secondary health metrics. The company reported promising Phase 2 results, with significant weight reduction in patients. Viking is also conducting Phase 3 trials for a subcutaneous version of VK2735.

investing.com2 min